These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19549706)

  • 21. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.
    Cella D; Motzer RJ; Rini BI; Cappelleri JC; Ramaswamy K; Hariharan S; Arondekar B; Bushmakin AG
    Value Health; 2018 Dec; 21(12):1413-1418. PubMed ID: 30502785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31].
    Trump D
    Urol Oncol; 2016 May; 34(5):251. PubMed ID: 25937427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commentary on "Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α." Tsimafeyeu I, Zart JS, Chung B, Kidney Cancer Research Bureau, Moscow, Russian Federation.: BJU Int 2013; 112(1):32-8. [Epub 2013 Jun 7]. doi: 10.1111/bju.12107.
    Boorjian S
    Urol Oncol; 2014 May; 32(4):514-5. PubMed ID: 24767689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.
    Dirican A; Kucukzeybek Y; Erten C; Somali I; Demir L; Can A; Payzin KB; Bayoglu IV; Akyol M; Yildiz Y; Koeseoglu M; Alacacioglu A; Tarhan MO
    Asian Pac J Cancer Prev; 2013; 14(3):2101-5. PubMed ID: 23679326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
    Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.
    Oudard S; Geoffrois L; Guillot A; Chevreau C; Deville JL; Falkowski S; Boyle H; Baciuchka M; Gimel P; Laguerre B; Laramas M; Pfister C; Topart D; Rolland F; Legouffe E; Denechere G; Amela EY; Abadie-Lacourtoisie S; Gross-Goupil M
    Eur J Cancer; 2016 Jul; 62():28-35. PubMed ID: 27192659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sunitinib for the treatment of metastatic renal cell carcinoma.
    Oudard S; Beuselinck B; Decoene J; Albers P
    Cancer Treat Rev; 2011 May; 37(3):178-84. PubMed ID: 20817406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma.
    Kucharz J; Giza A; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Bryniarski P; Herman R; Zygulska AL; Krzemieniecki K
    Med Oncol; 2016 Oct; 33(10):109. PubMed ID: 27573381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma].
    Bergmann L
    Onkologie; 2010; 33 Suppl 1():2-4. PubMed ID: 20164668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab
    Atkins MB; Rini BI; Motzer RJ; Powles T; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Gurney H; Oudard S; Uemura M; Lam ET; Grüllich C; Quach C; Carroll S; Ding B; Zhu QC; Piault-Louis E; Schiff C; Escudier B
    Clin Cancer Res; 2020 Jun; 26(11):2506-2514. PubMed ID: 32127394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
    Tannir NM; Jonasch E; Albiges L; Altinmakas E; Ng CS; Matin SF; Wang X; Qiao W; Dubauskas Lim Z; Tamboli P; Rao P; Sircar K; Karam JA; McDermott DF; Wood CG; Choueiri TK
    Eur Urol; 2016 May; 69(5):866-74. PubMed ID: 26626617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
    Herrmann E; Gerss J; Bierer S; Köpke T; Bolenz C; Hertle L; Wülfing C
    J Cancer Res Clin Oncol; 2009 Jan; 135(1):61-7. PubMed ID: 18592270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.
    Patil S; Figlin RA; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Motzer RJ
    Ann Oncol; 2011 Feb; 22(2):295-300. PubMed ID: 20657034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
    Lai JS; Beaumont JL; Diaz J; Khan S; Cella D
    Cancer; 2016 Jan; 122(2):287-95. PubMed ID: 26457466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.
    Blagoev KB; Wilkerson J; Stein WD; Motzer RJ; Bates SE; Fojo AT
    Cell Rep; 2013 Feb; 3(2):277-81. PubMed ID: 23395639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
    N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
    Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.